Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX-02 for Alport syndrome
ISRCTN12014920Phase 2Completed
- Sponsor
- Eloxx Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of exaluren in Alport syndrome, sponsored by Eloxx Pharmaceuticals. Primary endpoints: Incidence and characteristics of adverse events, Injection site reactions and 4 more. Started Oct 2022; status: completed.
02
Drugs
exaluren
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on ISRCTN12014920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12014920.